For the quarter ended March 2024, Collegium Pharmaceutical (COLL) reported revenue of $144.92 million, up 0.1% over the same period last year. EPS came in at $1.45, compared to $1.32 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $147.04 million, representing a surprise of -1.44%. The company delivered an EPS surprise of -2.68%, with the consensus EPS estimate being $1.49.While investors closely watch year-over-year changes in headline numbers -- revenue and earning ...